vs
科睿唯安（CLVT）与GE医疗（DHC）财务数据对比。点击上方公司名可切换其他公司
科睿唯安的季度营收约是GE医疗的1.5倍（$585.5M vs $379.6M），GE医疗净利率更高（-5.6% vs -6.9%，领先1.3%），GE医疗同比增速更快（-0.0% vs -1.4%），科睿唯安自由现金流更多（$78.9M vs $-166.4M），过去两年GE医疗的营收复合增速更高（1.2% vs -5.1%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
GE医疗是一家总部位于美国伊利诺伊州芝加哥市的医疗科技企业，业务涵盖四大板块：医疗影像设备，包括分子成像、CT、核磁共振、妇科健康筛查及X光系统；超声设备；患者护理解决方案，聚焦远程患者监测、麻醉呼吸护理、心脏诊断及婴幼儿护理；此外还涉及医药相关领域，是全球医疗行业的知名企业。
CLVT vs DHC — 直观对比
营收规模更大
CLVT
是对方的1.5倍
$379.6M
营收增速更快
DHC
高出1.4%
-1.4%
净利率更高
DHC
高出1.3%
-6.9%
自由现金流更多
CLVT
多$245.3M
$-166.4M
两年增速更快
DHC
近两年复合增速
-5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $585.5M | $379.6M |
| 净利润 | $-40.2M | $-21.2M |
| 毛利率 | 67.2% | — |
| 营业利润率 | 5.2% | -12.6% |
| 净利率 | -6.9% | -5.6% |
| 营收同比 | -1.4% | -0.0% |
| 净利润同比 | 61.3% | 75.7% |
| 每股收益（稀释后） | $-0.06 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTDHC
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $379.6M | ||
| Q3 25 | $623.1M | $388.7M | ||
| Q2 25 | $621.4M | $382.7M | ||
| Q1 25 | $593.7M | $386.9M | ||
| Q4 24 | $663.0M | $379.6M | ||
| Q3 24 | $622.2M | $373.6M | ||
| Q2 24 | $650.3M | $371.4M |
净利润CLVTDHC
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | $-21.2M | ||
| Q3 25 | $-28.3M | $-164.0M | ||
| Q2 25 | $-72.0M | $-91.6M | ||
| Q1 25 | $-103.9M | $-9.0M | ||
| Q4 24 | $-191.8M | $-87.4M | ||
| Q3 24 | $-65.6M | $-98.7M | ||
| Q2 24 | $-304.3M | $-97.9M |
毛利率CLVTDHC
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | — | ||
| Q3 25 | 65.0% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 65.1% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 66.2% | — | ||
| Q2 24 | 67.2% | — |
营业利润率CLVTDHC
| Q1 26 | 5.2% | — | ||
| Q4 25 | 6.7% | -12.6% | ||
| Q3 25 | 7.1% | -43.4% | ||
| Q2 25 | 1.1% | -24.5% | ||
| Q1 25 | -3.5% | -2.7% | ||
| Q4 24 | -9.4% | -26.1% | ||
| Q3 24 | 3.5% | -26.5% | ||
| Q2 24 | -36.9% | -23.0% |
净利率CLVTDHC
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | -5.6% | ||
| Q3 25 | -4.5% | -42.2% | ||
| Q2 25 | -11.6% | -23.9% | ||
| Q1 25 | -17.5% | -2.3% | ||
| Q4 24 | -28.9% | -23.0% | ||
| Q3 24 | -10.5% | -26.4% | ||
| Q2 24 | -46.8% | -26.3% |
每股收益（稀释后）CLVTDHC
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $-0.09 | ||
| Q3 25 | $-0.04 | $-0.68 | ||
| Q2 25 | $-0.11 | $-0.38 | ||
| Q1 25 | $-0.15 | $-0.04 | ||
| Q4 24 | $-0.27 | $-0.37 | ||
| Q3 24 | $-0.09 | $-0.41 | ||
| Q2 24 | $-0.46 | $-0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $105.4M |
| 总债务越低越好 | $4.3B | $2.4B |
| 股东权益账面价值 | $4.8B | $1.7B |
| 总资产 | $10.9B | $4.4B |
| 负债/权益比越低杠杆越低 | 0.89× | 1.47× |
8季度趋势，按日历期对齐
现金及短期投资CLVTDHC
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | $105.4M | ||
| Q3 25 | $318.7M | $201.4M | ||
| Q2 25 | $362.6M | $141.8M | ||
| Q1 25 | $354.0M | $302.6M | ||
| Q4 24 | $295.2M | $144.6M | ||
| Q3 24 | $388.5M | $256.5M | ||
| Q2 24 | $376.4M | $265.6M |
总债务CLVTDHC
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $2.4B | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | $3.1B | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — |
股东权益CLVTDHC
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $1.7B | ||
| Q3 25 | $4.9B | $1.7B | ||
| Q2 25 | $5.0B | $1.9B | ||
| Q1 25 | $5.0B | $1.9B | ||
| Q4 24 | $5.1B | $2.0B | ||
| Q3 24 | $5.5B | $2.0B | ||
| Q2 24 | $5.6B | $2.1B |
总资产CLVTDHC
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $4.4B | ||
| Q3 25 | $11.2B | $4.7B | ||
| Q2 25 | $11.4B | $4.8B | ||
| Q1 25 | $11.5B | $5.0B | ||
| Q4 24 | $11.5B | $5.1B | ||
| Q3 24 | $12.0B | $5.3B | ||
| Q2 24 | $12.1B | $5.3B |
负债/权益比CLVTDHC
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | 1.47× | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 0.88× | 1.56× | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.83× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.7M | $-19.6M |
| 自由现金流经营现金流 - 资本支出 | $78.9M | $-166.4M |
| 自由现金流率自由现金流/营收 | 13.5% | -43.8% |
| 资本支出强度资本支出/营收 | 9.5% | 38.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $333.9M | $-280.3M |
8季度趋势，按日历期对齐
经营现金流CLVTDHC
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | $-19.6M | ||
| Q3 25 | $181.1M | $-49.3M | ||
| Q2 25 | $116.3M | $53.0M | ||
| Q1 25 | $171.2M | $-3.2M | ||
| Q4 24 | $141.3M | $112.2M | ||
| Q3 24 | $202.9M | $21.1M | ||
| Q2 24 | $126.2M | $44.3M |
自由现金流CLVTDHC
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | $-166.4M | ||
| Q3 25 | $115.5M | $-89.8M | ||
| Q2 25 | $50.3M | $18.8M | ||
| Q1 25 | $110.3M | $-42.9M | ||
| Q4 24 | $59.1M | $-89.5M | ||
| Q3 24 | $126.3M | $-26.1M | ||
| Q2 24 | $60.3M | $3.3M |
自由现金流率CLVTDHC
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | -43.8% | ||
| Q3 25 | 18.5% | -23.1% | ||
| Q2 25 | 8.1% | 4.9% | ||
| Q1 25 | 18.6% | -11.1% | ||
| Q4 24 | 8.9% | -23.6% | ||
| Q3 24 | 20.3% | -7.0% | ||
| Q2 24 | 9.3% | 0.9% |
资本支出强度CLVTDHC
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | 38.7% | ||
| Q3 25 | 10.5% | 10.4% | ||
| Q2 25 | 10.6% | 8.9% | ||
| Q1 25 | 10.3% | 10.2% | ||
| Q4 24 | 12.4% | 53.1% | ||
| Q3 24 | 12.3% | 12.6% | ||
| Q2 24 | 10.1% | 11.0% |
现金转化率CLVTDHC
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
DHC
| Senior Housing Operating Portfolio Segment | $323.4M | 85% |
| Rental Income | $56.2M | 15% |
